These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 35926752)

  • 1. Targeted colonic release formulations of mesalazine - A clinical pharmaco-scintigraphic proof-of-concept study in healthy subjects and patients with mildly active ulcerative colitis.
    Varum F; Thorne H; Bravo R; Gilgen D; Hartig C; Nicolas GP; Wild D; Liakoni E; Haschke M
    Int J Pharm; 2022 Sep; 625():122055. PubMed ID: 35926752
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A novel coating concept for ileo-colonic drug targeting: proof of concept in humans using scintigraphy.
    Varum FJ; Hatton GB; Freire AC; Basit AW
    Eur J Pharm Biopharm; 2013 Aug; 84(3):573-7. PubMed ID: 23348235
    [TBL] [Abstract][Full Text] [Related]  

  • 3. 5-aminosalicylic acid release from a new controlled-release mesalazine formulation during gastrointestinal transit in healthy volunteers.
    Brunner M; Lackner E; Exler PS; Fluiter HC; Kletter K; Tschurlovits M; Dudczak R; Eichler HG; Müller M
    Aliment Pharmacol Ther; 2006 Jan; 23(1):137-44. PubMed ID: 16393291
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mesalazine Modified-Release Tablet in the Treatment of Ulcerative Colitis in the Active Phase: A Chinese, Multicenter, Single-Blind, Randomized Controlled Study.
    Sun J; Yuan Y
    Adv Ther; 2016 Mar; 33(3):400-9. PubMed ID: 26898569
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Gastrointestinal transit and release of 5-aminosalicylic acid from 153Sm-labelled mesalazine pellets vs. tablets in male healthy volunteers.
    Brunner M; Greinwald R; Kletter K; Kvaternik H; Corrado ME; Eichler HG; Müller M
    Aliment Pharmacol Ther; 2003 May; 17(9):1163-9. PubMed ID: 12752353
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Gastrointestinal transit and release of mesalazine tablets in patients with inflammatory bowel disease.
    Healey JN
    Scand J Gastroenterol Suppl; 1990; 172():47-51. PubMed ID: 2353171
    [TBL] [Abstract][Full Text] [Related]  

  • 7. OPTICORE™, an innovative and accurate colonic targeting technology.
    Varum F; Freire AC; Bravo R; Basit AW
    Int J Pharm; 2020 Jun; 583():119372. PubMed ID: 32344022
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Population pharmacokinetics and IVIVC for mesalazine enteric-coated tablets.
    Zhang Y; Wo SK; Leng W; Gao F; Yan X; Zuo Z
    J Control Release; 2022 Jun; 346():275-288. PubMed ID: 35461968
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mesalazine Modified-Release Tablet in the Treatment of Ulcerative Colitis in the Remission Phase: A Chinese, Multicenter, Single-Blind, Randomized Controlled Study.
    Sun J; Yuan Y
    Adv Ther; 2016 Mar; 33(3):410-22. PubMed ID: 26905266
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Double-blind comparative study of sulfasalazine and controlled-release mesalazine tablets in the treatment of active ulcerative colitis.
    Munakata A; Yoshida Y; Muto T; Tsuchiya S; Fukushima T; Hiwatashi N; Kobayashi K; Kitano A; Shimoyama T; Inoue M
    J Gastroenterol; 1995 Nov; 30 Suppl 8():108-11. PubMed ID: 8563868
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mesalazine (5-aminosalicylic acid) micropellets show similar efficacy and tolerability to mesalazine tablets in patients with ulcerative colitis--results from a randomized-controlled trial.
    Raedler A; Behrens C; Bias P
    Aliment Pharmacol Ther; 2004 Dec; 20(11-12):1353-63. PubMed ID: 15606398
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Distribution of mesalazine enemas in active and quiescent ulcerative colitis.
    van Bodegraven AA; Boer RO; Lourens J; Tuynman HA; Sindram JW
    Aliment Pharmacol Ther; 1996 Jun; 10(3):327-32. PubMed ID: 8791959
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mesalazine granules are superior to Eudragit-L-coated mesalazine tablets for induction of remission in distal ulcerative colitis - a pooled analysis.
    Leifeld L; Pfützer R; Morgenstern J; Gibson PR; Marakhouski Y; Greinwald R; Mueller R; Kruis W
    Aliment Pharmacol Ther; 2011 Nov; 34(9):1115-22. PubMed ID: 21923715
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Scintigraphic study of gastrointestinal transit and disintegration sites of mesalazine tablets labeled with technetium-99m.
    Sciarretta G; Furno A; Mazzoni M; Ferrieri A; Malaguti P
    Scand J Gastroenterol; 1993 Sep; 28(9):783-5. PubMed ID: 8235433
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In-vitro characterization of 5-aminosalicylic acid release from MMX mesalamine tablets and determination of tablet coating thickness.
    Tenjarla S; Abinusawa A
    Adv Ther; 2011 Jan; 28(1):62-72. PubMed ID: 21088944
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Development of a zero-order sustained-release tablet containing mesalazine and budesonide intended to treat the distal gastrointestinal tract in inflammatory bowel disease.
    Gareb B; Eissens AC; Kosterink JGW; Frijlink HW
    Eur J Pharm Biopharm; 2016 Jun; 103():32-42. PubMed ID: 27000751
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical pharmacokinetics of slow release mesalazine.
    De Vos M
    Clin Pharmacokinet; 2000 Aug; 39(2):85-97. PubMed ID: 10976656
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Gastrointestinal release behaviour of modified-release drug products: dynamic dissolution testing of mesalazine formulations.
    Goyanes A; Hatton GB; Merchant HA; Basit AW
    Int J Pharm; 2015 Apr; 484(1-2):103-8. PubMed ID: 25721685
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Colonic spreading of a non-chlorofluorocarbon mesalazine rectal foam enema in patients with quiescent ulcerative colitis.
    Wilding IR; Kenyon CJ; Chauhan S; Hooper G; Marshall S; McCracken JS; Staab HJ; Armbrecht J
    Aliment Pharmacol Ther; 1995 Apr; 9(2):161-6. PubMed ID: 7605856
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The colon targeting efficacies of mesalazine medications and their impacts on the gut microbiome.
    McCoubrey LE; Seegobin N; Sangfuang N; Moens F; Duyvejonck H; Declerck E; Dierick A; Marzorati M; Basit AW
    J Control Release; 2024 May; 369():630-641. PubMed ID: 38599548
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.